The FDA approved two new indications for NewTract's UroLift System, which is used in the treatment of enlarged prostate or benign prostatic hyperplasia.
Here's what you should know:
1. After the recent approvals, UroLift can now be used on patients with obstructive median lobes, as well as those as young as 45 years old.
2. The UroLift system was previously contraindicated in patients with an obstructive median lobe, and only cleared for men that were 50 years or older.
3. A new study provided enough clinical evidence to earn the additional clearances.
NeoTract President Dave Amerson said, "We are excited that more men with enlarged prostate[s] are now eligible for treatment with the UroLift System. The clinical data we have amassed on the UroLift System ... has solidified the product’s position as an important standard-of-care treatment for men with [benign prostatic hyperplasia] and is further bolstered by these expanded indications. We are diligently training current UroLift users on how to treat obstructive median lobes with the UroLift System so they continue to see optimal patient outcomes."